文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-PSMA-11 PET/CT在转移性去势抵抗性前列腺癌中的异质性:基因组特征及其与阿比特龙疗效的关联

Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-01-31

本研究回顾性纳入153例转移性去势抵抗性前列腺癌(mCRPC)患者,分析[68Ga]Ga-PSMA-11 PET/CT空间异质性(SUVhetero)与循环肿瘤DNA(ctDNA)特征及新型激素药物(NHA)疗效的关系。结果显示SUVhetero越高ctDNA%越高,SUVhetero不可测者阿比特龙治疗PSA缓解率更高(52% vs. 90%,p=0.036)。

要点

  • SUVhetero越高,ctDNA%越高(Spearman's rho=0.278,p<0.002)。
  • SUVhetero不可测者阿比特龙PSA缓解率高于高SUVhetero者(52% vs. 90%,p=0.036)。
  • SUVmax-mean较高者阿比特龙PSA缓解率高于较低者(83.3% vs. 53.3%,p=0.024)。

核心结论

  • PSMA摄取的空间异质性与ctDNA特征及NHA治疗缓解率相关。

研究设计与样本

  • 回顾性研究,纳入153例接受[68Ga]Ga-PSMA-11 PET/CT与ctDNA测序间隔小于2周的mCRPC患者。
  • SUVhetero定义为每个PSMA阳性病灶SUVmean的方差;SUVmax-mean为SUVmax减去SUVmean。
  • 接受阿比特龙治疗且有完整随访记录者纳入PSA缓解率分析,共60例。
  • PSA缓解定义为较基线下降大于50%。

主要发现

  • ctDNA检出率为65%(100/153)。
  • SUVhetero越高,ctDNA%越高(Spearman's rho=0.278,p<0.002)。
  • 60例PSA缓解分析患者中位随访19.3个月(IQR 16.2-23.2)。
  • SUVhetero不可测者阿比特龙PSA缓解率高于高SUVhetero者(52% vs. 90%,p=0.036)。
  • SUVmax-mean较高者阿比特龙PSA缓解率高于较低者(83.3% vs. 53.3%,p=0.024)。

关键数值与推荐

  • SUVmax-mean与SUVhetero高度相关(Spearman's rho=0.833,p<0.0001)。
  • 外部队列证实基线SUVmax-mean值与恩扎卢胺治疗缓解率相关。
  • AR、DNA损伤修复通路、TP53、AR相关通路、细胞周期通路或WNT通路存在改变者SUVmax-mean值高于无改变者(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the impact of the spatial heterogeneity of prostate-specific membrane antigen (PSMA) uptake on circulating tumor DNA (ctDNA) characteristics and the response rate to new hormonal agent (NHA) treatment. METHODS: This retrospective study included 153 patients with metastatic castration-resistant prostate cancer (mCRPC) who underwent gallium-68 [68 Ga]Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) and ctDNA sequencing with a less than 2-week interval. SUVhetero was defined as the variance of SUVmean for each PSMA-positive lesion. SUVmax-mean was obtained by subtracting the SUVmax by the SUVmean. Patients receiving abiraterone treatment after [68 Ga]Ga-PSMA-11 PET/CT and ctDNA sequencing and with complete follow-up record were included into prostate-specific antigen (PSA) response rate analysis. PSA response was defined as a reduction of greater than 50% from baseline. RESULTS: The ctDNA detection rate was 65% (100/153). Higher SUVhetero value contributed to higher ctDNA% (Spearman's rho = 0.278, p < 0.002). A total of 60 patients were included in PSA response rate analysis. The median follow-up was 19.3 (IQR 16.2-23.2) months. Compare to patients with higher SUVhetero value, patients with NA SUVhetero had a higher PSA response rate (52% vs. 90%, p = 0.036). A higher SUVmax-mean value was strongly correlated with higher SUVhetero (Spearman's rho = 0.833, p < 0.0001). Patients with higher SUVmax-mean value also had a higher PSA response rate compared to patients with lower SUVmax-mean value (83.3% vs. 53.3%, p = 0.024). An external cohort confirmed baseline SUVmax-mean value was associated with enzalutamide treatment response rate. Patients with alterations in AR, DNA damage repair pathway, TP53, AR-associated pathway, cell cycle pathway, or WNT pathway had higher SUVmax-mean value compared to those without (p < 0.05). CONCLUSION: Spatial heterogeneity of the PSMA uptake was associated with ctDNA characteristics and response rate to NHA treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pan J, Zhao J, Ni X, et al. Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response. Eur J Nucl Med Mol Imaging. 2023. PMID: 36719427. doi:10.1007/s00259-023-06123-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。